Novel biomarkers GEP/ABCB5 regulate response to adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma.

Charing Ching-Ning Chong,Siu Tim Cheung,Yue-Sun Cheung,Anthony Wing-Hung Chan,Stephen Lam Chan,Simon Chun-Ho Yu,Paul Bo-San Lai

Hepatobiliary & Pancreatic Diseases International（2018）

引用 4|浏览16

暂无评分

摘要

Adjuvant TACE can only provide survival benefits for patients in the intermediate risk group (either GEP+/ABCB5- or GEP-/ABCB5+). A larger clinical study is warranted to confirm its role in patient selection for adjuvant TACE.

查看译文

关键词

Adjuvant therapy,Hepatocellular carcinoma,Drug transporter,Transarterial chemoembolisation,Granulin-epithelin precursor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要